Wantai Biopharm Advances Hepatitis B Virus Detection Technology and Chronic Disease POCT Diagnostic System Construction
Recently, Wantai Biopharm was officially awarded the "R&D and Application of Multi-Scenario and Multi-Modal Rapid Detection Technology for Hepatitis B Virus" national major science and technology project (Project No. 2025ZD01906800). This marks a significant achievement for Wantai Biopharm in the field of Hepatitis B prevention and control diagnostics, as the company¡¯s technical research and system integration capabilities have once again gained national authoritative recognition. Wantai Biopharm will lead the entire innovation chain in this field, from technological research and development to clinical transformation.
As one of the key participants, Wantai Biopharm collaborates with numerous clinical and research institutions to advance the "Development and Application of Multi-Modal POCT Diagnostic Technology for Major Chronic Diseases in Population Monitoring and Prognosis"¡ªan independent R&D and system innovation project aimed at early diagnosis and dynamic monitoring technologies for major chronic diseases in China.
Autobio Launches Its First Microbial Solution Laboratory in Hungary
On February 2, Autobio, in partnership with Corden Labordiagnosztika, inaugurated Hungary's first laboratory fully equipped with Autobio's Total Laboratory Microbial Solutions at Budapest's Bajcsy-Zsilinszky K¨®rh¨¢z ¨¦s Rendelőint¨¦zet. This lab implements a complete, automated workflow that enhances standardization and boosts the efficiency and accuracy of clinical microbial testing and infection diagnosis.
Currently, Autobio'¡¯s global expansion has made significant progress in the European market: the fully automated microbial mass spectrometry detection system has been successfully exported to over 20 European countries and regions, including the UK, France, Italy, and Russia. The fully automated microbial identification and antimicrobial susceptibility testing system has also been awarded an international invention patent by the European Patent Office. This system innovatively combines colorimetry and turbidimetry to achieve the world¡¯s first automated detection of Aspergillus susceptibility, addressing a core industry challenge. Additionally, 383 products have successfully passed EU IVDR CE certification, including several Class D products of the highest risk category, earning wide recognition and trust in the European market.
Kingmed Diagnostics First to Launch MALDI-TOF MS Solution for M Protein
Accurate detection of M protein is critical for the clinical diagnosis and efficacy assessment of plasma cell diseases, such as multiple myeloma. Traditional detection methods like immunofixation electrophoresis, widely used in clinical practice, have limitations such as insufficient sensitivity, inaccurate quantification, and significant subjective influences. These challenges are especially prominent when patients are treated with drugs like Daratumumab (DARA), which can interfere with detection and complicate the clinical diagnostic needs.
This dilemma is now being resolved. Recently, Kingmed Diagnostics (603882) has pioneered the development of a full-process M protein solution based on MALDI-TOF mass spectrometry technology. This solution enables precise tracking of M protein from ¡°present/absent¡± and ¡°what it is¡± to ¡°how much there is,¡± pushing China¡¯s plasma cell disease detection to align with international advanced levels and contributing to the advancement of precision diagnosis and treatment for hematological diseases.
Wondfo Biotech Launches New Detection Solution for Nipah Virus
Focusing on public health emergency needs, Wondfo Biotech continues to strengthen its technological advancements with the launch of a new detection solution for the Nipah virus. This new platform features a colloidal gold-based test kit for antigen detection as well as an IgM/IgG antibody detection kit.
The antigen detection kit provides results in just 15 minutes, making it an effective tool for quick screening during the acute phase of infection. It supports both blood and swab sample types, enabling fast virus detection within 15 minutes to meet the urgent screening and control needs during the acute infection phase. This product has completed sample preparation and will soon undergo evaluation at international terminals to support global Nipah virus control with rapid detection capabilities.
